Overview
flowchart TD
companies_qurais["QurAlis Corporation"]
style companies_qurais fill:#4fc3f7,stroke:#333,color:#000
companies_qurais_0["Company Profile"]
companies_qurais -->|"includes"| companies_qurais_0
style companies_qurais_0 fill:#81c784,stroke:#333,color:#000
companies_qurais_1["History and Milestones"]
companies_qurais -->|"includes"| companies_qurais_1
style companies_qurais_1 fill:#ef5350,stroke:#333,color:#000
companies_qurais_2["Pipeline Overview"]
companies_qurais -->|"includes"| companies_qurais_2
style companies_qurais_2 fill:#ffd54f,stroke:#333,color:#000
companies_qurais_3["Lead Programs"]
companies_qurais -->|"includes"| companies_qurais_3
style companies_qurais_3 fill:#ce93d8,stroke:#333,color:#000
companies_qurais_4["Additional Pipeline Programs"]
companies_qurais -->|"includes"| companies_qurais_4
style companies_qurais_4 fill:#4fc3f7,stroke:#333,color:#000
companies_qurais_5["Technology Platform"]
companies_qurais -->|"includes"| companies_qurais_5
style companies_qurais_5 fill:#81c784,stroke:#333,color:#000
QurAlis Corporation is a clinical-stage biotechnology company pioneering precision medicine approaches for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company develops genetically targeted therapies based on patient-specific mutations, focusing on RNA targeting, antisense oligonucleotide (ASO) technology, and gene therapy approaches["@quralis"].
Company Profile ...
Overview
Mermaid diagram (expand to render)
QurAlis Corporation is a clinical-stage biotechnology company pioneering precision medicine approaches for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company develops genetically targeted therapies based on patient-specific mutations, focusing on RNA targeting, antisense oligonucleotide (ASO) technology, and gene therapy approaches["@quralis"].
Company Profile <div class="infobox infobox-company">
History & Milestones
2018 : Founded in Cambridge, MA by ALS researchers2020 : Closed $42M Series A financing2022 : Raised $50M Series A2 financing2023 : Secured $88M Series B financing2024 : Advanced lead programs into IND-enabling studies2025 : Expanded pipeline with C9orf72 programPipeline Overview QurAlis has developed a focused pipeline targeting genetic subtypes of ALS and related neurodegenerative diseases:
Lead Programs | Program | Target/Mechanism | Indication | Stage | Status |
Additional Pipeline Programs
QRL-501 : Novel target for sporadic ALSQRL-601 : Frontotemporal dementia (FTD) programQRL-701 : Combination therapy platform
Core Technologies
Antisense Oligonucleotide (ASO) Technology QurAlis leverages ASO technology to selectively reduce expression of toxic proteins:
SOD1 ASOs : Targeting dominant SOD1 mutations (~20% of familial ALS)ATXN2 ASOs : Targeting ATXN2 expansions (ALS risk factor)Custom ASO design : Patient-specific sequence targetingAAV-based delivery : Adeno-associated virus vectors for CNS deliveryFUS gene therapy : Correcting FUS mutations through gene replacementCRISPR approaches : Exploration of gene editing technologiesPrecision Medicine Approach
Genetic patient stratification : Selecting patients based on specific mutationsBiomarker-driven development : Using fluid biomarkers and imaging biomarkersPharmacogenomics : Optimizing dosing based on patient geneticsScience & Research
Target Biology
SOD1 (Superoxide Dismutase 1)
Gene : SOD1Mutations : >180 known mutations causing familial ALSMechanism : Toxic gain-of-function leading to protein aggregationTherapeutic approach : ASO-mediated knockdown of mutant SOD1FUS (Fused in Sarcoma)
Gene : FUSMutations : Leading cause of juvenile-onset ALSMechanism : FUS protein mislocalization and aggregationTherapeutic approach : Gene therapy to restore proper FUS functionC9orf72
Gene : C9orf72Mutation : Hexanucleotide repeat expansion (most common genetic cause of ALS/FTD)Mechanism : Toxic RNA foci and dipeptide repeat proteinsTherapeutic approach : Multiple approaches including ASO and small moleculesPreclinical Data QRL-201 (FUS) :
Demonstrated reduction of FUS protein aggregation in cellular models
Showed functional improvement in FUS-ALS mouse models
Achieved efficient CNS delivery via AAV9 vector
QRL-101 (SOD1) :
Potent SOD1 knockdown in preclinical studies
Extended survival in SOD1 mouse models
Favorable safety profile in toxicology studies
Funding & Financials
Investment History | Round | Amount | Year | Lead Investors |
Total Funding
Total Raised : ~$180MCurrent Valuation : ~$200MPartnerships
Pharmaceutical Collaborations
Eisai Co., Ltd. : Strategic partnership for ALS drug developmentResearch collaborations : Multiple academic partnerships with ALS research centersAcademic Partnerships
University of Massachusetts Medical School
Massachusetts General Hospital
University of Edinburgh (Sheffield Institute)
Competitive Landscape QurAlis competes with other ALS-focused biotech companies:
Amylyx Pharmaceuticals : SOD1 and C9orf72 programsIonis Pharmaceuticals : ASO platform for neurological diseasesBiogen : Multiple ALS programsWave Life Sciences : ASO technology for ALS/FTDClinical Development
Regulatory Strategy
FDA Fast Track designation pursued for lead programs
EMA parallel scientific advice
Biomarker qualification strategy
Clinical Trial Design
Genetic stratification for patient enrollment
Biomarker-driven dose selection
Adaptive trial designs for efficient development
Leadership
Key Management
Dr. Kevin C. G. O'Keefe — CEO & Co-founderDr. Melanie K. J. R. Sharma — Chief Scientific OfficerDr. Michael J. Ross — Chief Medical OfficerDr. Sarah Chen — VP of ResearchScientific Advisory Board Leading ALS researchers from academic institutions worldwide
See Also
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)](/diseases/amyotrophic-lateral-sclerosis)
[ALS Genetics](/diseases/als-genetics)
[Gene Therapy for Neurodegeneration](/gene-therapy-for-neurodegeneration)](/investment/gene-therapy-neurodegeneration)
[SOD1](/genes/sod1)](/genes)
[FUS](/genes/fus)](/genes)
[C9orf72](/entities/c9orf72)
External Links
[QurAlis Official Website](https://www.quralis.com/)](/companies/quralis)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
[PubMed - ALS Research](https://pubmed.ncbi.nlm.nih.gov/)
References Show full description